Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (101-110 of 344) with videos related to

Pageof 35
Sort By:
Oncology|March 2, 2011
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eatKohei Shitara, Seiji Ito, Akira Sawaki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 13, 2006
[Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]Kohei Shitara, Masaki Munakata, Atsushi Ishiguro, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 10, 2025
Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trialsAndrew J Martin, Yu Yang Soon, Katrin Marie Sjoquist, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2016
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumorsToshihiko Doi, Kohei Shitara, Takashi Kojima, et al.
Annals of Surgical Oncology|October 31, 2025
Is Surgery Necessary for Stage IVB Gastric Cancer Showing Clinical Complete Response to Chemotherapy or Systemic Cancer Therapy?Takumi Habu, Shinpei Ushiyama, Izuma Nakayama, et al.
Japanese Journal of Clinical Oncology|April 25, 2020
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumorsKohei Shitara, Kentaro Yamazaki, Takahiro Tsushima, et al.
Cancer Science|December 8, 2022
Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinomaKohei Shitara, Akihito Kawazoe, Akihiro Hirakawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 15, 2007
[A case of unresectable advanced pancreatic cancer treated by S-1 with concurrent radiotherapy]Atsushi Ishiguro, Masaki Munakata, Kohei Shitara, et al.
Journal for Immunotherapy of Cancer|September 30, 2025
Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapySung Hee Lim, Takeshi Kuwata, Minae An, et al.
Surgical Case Reports|December 20, 2021
Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case reportKimimasa Sasaki, Shin Kobayashi, Masashi Kudo, et al.
Pageof 35

Showing results (101-110 of 344) with videos related to

Sort By:
Pageof 35
Oncology|March 2, 2011
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eatKohei Shitara, Seiji Ito, Akira Sawaki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 13, 2006
[Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]Kohei Shitara, Masaki Munakata, Atsushi Ishiguro, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 10, 2025
Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trialsAndrew J Martin, Yu Yang Soon, Katrin Marie Sjoquist, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2016
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumorsToshihiko Doi, Kohei Shitara, Takashi Kojima, et al.
Annals of Surgical Oncology|October 31, 2025
Is Surgery Necessary for Stage IVB Gastric Cancer Showing Clinical Complete Response to Chemotherapy or Systemic Cancer Therapy?Takumi Habu, Shinpei Ushiyama, Izuma Nakayama, et al.
Japanese Journal of Clinical Oncology|April 25, 2020
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumorsKohei Shitara, Kentaro Yamazaki, Takahiro Tsushima, et al.
Cancer Science|December 8, 2022
Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinomaKohei Shitara, Akihito Kawazoe, Akihiro Hirakawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 15, 2007
[A case of unresectable advanced pancreatic cancer treated by S-1 with concurrent radiotherapy]Atsushi Ishiguro, Masaki Munakata, Kohei Shitara, et al.
Journal for Immunotherapy of Cancer|September 30, 2025
Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapySung Hee Lim, Takeshi Kuwata, Minae An, et al.
Surgical Case Reports|December 20, 2021
Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case reportKimimasa Sasaki, Shin Kobayashi, Masashi Kudo, et al.
Pageof 35